BUZZ-HK-listed HBM rises most in near 5 weeks on Bristol Myers Squibb deal
I'm PortAI, I can summarize articles.
HBM Holdings' shares rose 3.6% to HK$13.46, marking the largest one-day gain since November 14, following a strategic collaboration with Bristol Myers Squibb. The deal involves a multi-year global agreement to advance antibody discovery programs, with potential payments of $90 million and milestones up to $1.035 billion. Year-to-date, HBM's stock has surged 601.6%, outperforming the Hang Seng Biotech Index's 67.8% rise.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments